Skip to main content

Amylyx Pharmaceuticals, Inc.

AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001658551

In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.

13F holders, Q2 2026

Institutional positions in Amylyx Pharmaceuticals, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
206
+37 vs. Q1 2026
Shares held
115.0M
+5.82M (+5.3%) vs. Q1 2026
Total value
$2.07B
+$549.0M (+36.2%) vs. Q1 2026
New holders
50
71 more added
Sold out
13
60 more reduced

2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q1 2026: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting AMLX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2026: 206 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 0 institutionsQ1 2022: 72 institutionsQ2 2022: 78 institutionsQ3 2022: 95 institutionsQ4 2022: 133 institutionsQ1 2023: 147 institutionsQ2 2023: 154 institutionsQ3 2023: 170 institutionsQ4 2023: 178 institutionsQ1 2024: 143 institutionsQ2 2024: 119 institutionsQ3 2024: 110 institutionsQ4 2024: 122 institutionsQ1 2025: 136 institutionsQ2 2025: 131 institutionsQ3 2025: 169 institutionsQ4 2025: 180 institutionsQ1 2026: 171 institutionsQ2 2026: 206 institutions
Value heldQ2 2026: $2.07B
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $0Q1 2022: $299.9MQ2 2022: $512.9MQ3 2022: $1.05BQ4 2022: $1.79BQ1 2023: $1.51BQ2 2023: $1.18BQ3 2023: $1.08BQ4 2023: $887.4MQ1 2024: $141.5MQ2 2024: $82.9MQ3 2024: $140.8MQ4 2024: $188.3MQ1 2025: $261.6MQ2 2025: $523.6MQ3 2025: $1.49BQ4 2025: $1.36BQ1 2026: $1.59BQ2 2026: $2.07B
Institutions holding AMLX and their total value by quarter
QuarterHoldersValue
Q2 2026206$2.07B
Q1 2026171$1.59B
Q4 2025180$1.36B
Q3 2025169$1.49B
Q2 2025131$523.6M
Q1 2025136$261.6M
Q4 2024122$188.3M
Q3 2024110$140.8M
Q2 2024119$82.9M
Q1 2024143$141.5M
Q4 2023178$887.4M
Q3 2023170$1.08B
Q2 2023154$1.18B
Q1 2023147$1.51B
Q4 2022133$1.79B
Q3 202295$1.05B
Q2 202278$512.9M
Q1 202272$299.9M
Q4 20210$0
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q2 2026

Shares, value and share of portfolio for each institution holding Amylyx Pharmaceuticals, Inc.; share changes are against Q1 2026.

Institutions holding AMLX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Jupiter Topco LLC5,236,102$94.0M0.04%+5,236,102New
Commodore Capital LP5,650,000$101.5M6.04%00.0%Unchanged
TCG Crossover Management, LLC6,243,812$112.1M2.70%00.0%Unchanged
Perceptive Advisors LLC8,334,882$149.7M2.32%+50,000+0.6%Added
BlackRock, Inc.8,827,085$158.5M0.00%−1,7510.0%Reduced
FMR LLC16,727,909$300.4M0.01%+97,368+0.6%Added
Squarepoint Ops LLC0$00.00%−114,877−100.0%Sold out
Point72 Asset Management, L.P.0$00.00%−106,535−100.0%Sold out
EAM Investors, LLC0$00.00%−53,256−100.0%Sold out
Integrated Quantitative Investments LLC0$00.00%−27,234−100.0%Sold out
Headlands Technologies LLC0$00.00%−19,814−100.0%Sold out
Verition Fund Management LLC0$00.00%−13,264−100.0%Sold out
Landscape Capital Management, L.L.C.0$00.00%−12,226−100.0%Sold out
MAI Capital Management0$00.00%−9,014−100.0%Sold out
ACT Capital Management, LLC0$00.00%−9,000−100.0%Sold out
Meeder Asset Management Inc0$00.00%−661−100.0%Sold out
Dunhill Financial, LLC0$00.00%−600−100.0%Sold out
Stone House Investment Management, LLC0$00.00%−73−100.0%Sold out
Ameritas Advisory Services, LLC0$00.00%−3−100.0%Sold out
Janus Henderson Group PLC––––Not filed
CWM, LLC––––Not filed